Switzerland leads in talent competitiveness, followed by Singapore, the United States, Denmark, and the Netherlands
In 2023, life sciences—including pharmaceuticals, vitamins, and diagnostics—made up 38.5% of Swiss exports
Switzerland ranks 10th worldwide for the number of active biotech patents within its territory
Switzerland offers seamless market access, top talent, and a business-friendly ecosystem. 20 percent of European Life Science companies have already chosen Switzerland as their HQ location. Find out how Switzerland can help you scale and thrive in Europe.

Switzerland Global Enterprise is delighted to partner again with the Swiss Biotech Association and organize the Side Visits Program for the international delegations of the Global Village, taking place on Wednesday, 28 April 2027, following the Swiss Biotech Day (26-27 April 2027). Further details about the program will be announced in February 2027. Discover more about the Global Village participation packages, associated benefits and deadlines.

Develop partnerships to scale your business
The Swiss life science ecosystem is made up of innovative start-ups and multinational giants such as Roche, Novartis, Bayer, Abbott, Merck, Biogen, CSL Behring, Baxter, Johnson & Johnson, Hamilton, and Medtronic. These companies benefit from Switzerland’s experienced cluster along the entire value chain to develop, produce and market new products and services - from drug discovery to commercialization, all in one place.
If you are looking to set up supply chain and other headquarter functions, Switzerland provides excellent infrastructure and solutions for managing revenues and risks.

Enjoy a safe and innovative legal framework
Considering European expansion? Life Science companies favor Switzerland as a headquarter location for many reasons. Its central location, various trade agreements and progressive regulations make it easy for companies to tap into the European market, made up of almost 500 million consumers. A business-friendly environment and competitive corporate and personal tax rates provide further advantages for setting up headquarter functions in Switzerland. 20% of European Life Science companies have already chosen Switzerland as their HQ location, representing over 90 companies with active clinical trials. Life Science companies that already settled in Switzerland include Bluebird Bio, Roivant Sciences, BeiGene, Alnylam, Incyte, Biogen, Moderna, Luye Pharma, Align Technology, and Amgen.

Collaborate pragmatically with leading research institutes
Switzerland’s strong collaboration between science and industry accelerates the path from lab to market. In a 2021 analysis by Biotechgate, Switzerland has the strongest product pipeline in Europe, after the UK. With CHF 9 billion invested by pharma alone in 2020, and two-thirds of all R&D spending coming from private firms, Switzerland ranks among the top globally in R&D intensity. 14 Swiss companies are ranked among the top 500 companies worldwide in terms of corporate research spending, with Roche ranked in 8th position and Novartis in 14th position.
Learn how your company can benefit from Switzerland’s unique focus on applied science.

Attract and retain the best people
Benefit from Switzerland’s talent pool - because it’s vast! Switzerland is a hub for PhD professionals in Life Sciences and related disciplines, with its top-ranking universities attracting diverse doctoral talent. Switzerland provides a rich talent pool for pharmaceutical, biotechnology, medical technology and digital health. Switzerland's excellent quality of life, favorable tax policies and flexible work arrangements make it an attractive destination for C-level executives. Its renowned apprenticeship system ensures well-trained lab technicians or QC analysts with practical skills for the highly regulated life sciences sector and biologics manufacturing processes.
Find out more about talent in the Swiss health industry.
Dr. Katja Buller
Vice President and Head of Corporate Affairs International, BiogenAnurag Mantri, Executive Director & Global Chief Financial Officer, Glenmark Pharmaceuticals

Nov 16, 2026 · 1 min read

Michaela Mersetzky, Switzerland Global Enterprise
Nov 3, 2026 · 2 min read

James Waldron
Sep 8, 2025 · 1 min read

Nenna Ohaka
Oct 15, 2025 · 1 min read



